AllDocs -> cancers

For Internal Use Only. Not For Use With The Public. This material is intended for insurance informational purposes only and is not personal medical advice for clients. Ovarian Cancer Ovarian cancer accounts for 5% of all cancers in women and is most common in the 40-70 year age group. The incidence is increasing in highly industrialized countries and it is more common in women of higher socioeconomic status. The latter may be due to the smaller number of pregnancies in that group. Women who have not borne children are at an increased risk of ovarian cancer . Other risk factors include: early menopause, high fat diet, positive family history, and previous irradiation of the pelvic organs. Factors that suppress ovulation, such as pregnancy and the use of birth control pills, protect against this cancer . The mortality risk associated with ovarian cancer varies with the stage ...

Comparison of Statistical Methods for Classification of Ovarian Cancer Using Mass Spectrometry Data Baolin Wu 1 , Tom Abbott 2 , David Fishman 5 , Walter McMurray 2 , Gil Mor 3 , Kathryn Stone 2 , David Ward 4 , Kenneth Williams 2 , and Hongyu Zhao *1 1 Department of Epidemiology and Public Health 2 HHMI Biopolymer/Keck Laboratory 3 Department of Obstetrics and Gynecology 4 Department of Genetics, Yale University School of Medicine, New Haven,CT,USA 5 Department of OB/GYN, Northwestern University School of Medicine, Chicago,IL,USA 1 Abstract Motivation: Novel methods, both molecular and statistical, are urgently needed to take advantage of recent advances in biotechnology and the ...

146 N ORTHERN C ALIFORNIA C ANCER C ENTER , Cancer Incidence and Mortality in the Greater San Francisco Bay Area Ovarian Cancer • Incidence of ovarian cancer decreased between 1988 and 2000 (Table 1). • White females had higher incidence rates of ovarian cancer than females of other racial/ethnic groups (Table 1). • Ovarian cancer was uncommon in young adults, but incid ence rates rose with age, peaking in females 75-79 years old, but compared to most cancers, cases do occur at younger ages (Table 2). • Ovarian cancer incidence rates were similar across all counties in the Greater San Francisco Bay Area (Table 3). TABLE 1. Ovarian Cancer . Annual Case Counts, Age-Adjusted Incidence Rates per 100,000 Females, ...

Updated January 2002 What is gynecologic cancer ? Gynecologic cancer is the uncontrolled growth and spread of abnormal cells originating in the female reproductive organs, including the cervix, ovaries, uterus, fallopian tubes, vagina and vulva. What causes gynecologic cancer ? Biomedical research has discovered that some genes, called oncogenes and tumor suppressor genes, promote the growth of cancer . You can acquire these genetic mutations during life (e.g. through smoking, aging or environmental influences) or you can inherit these mutations from your parents or grandparents. Can gynecologic cancer be prevented? Diet, exercise and lifestyle choices play a significant role in the prevention of cancer . Additionally, knowing your family history can increase your chance of early diagnosis and can help you take action towards prevention. ...

Royal Society of Medicine Symposia Key Advances in the Clinical Management Ovarian Cancer Abstracts & Biographies Page 2 2 Contents PROFESSOR RI HORNUNG ..3 PROFESSOR IAN JACOBS MD MRCOG ..4 PROFESSOR STANLEY KAYE ..5 DR KATHERINE ORTON MBBS, MRCGP, DCH, DRCOG, D.ADD.BEHAV.. 6 DR PAUL PHAROAH ..7 PROFESSOR GORDON RUSTIN .8 MR PAT SOUTTER MD MSC FRCOG 9 DR ADRIAN TOOKMAN FRCP .10 NOTES ..12 N.B. The abstracts and biographies are presented alphabetically, rather than in programme order to overcome late additions and any changes to the programme that may occur after the print run. Page 3 3 Key advances in the Clinical Management: Ovarian Cancer Thursday 23 January 2003 ...

ANGIOGENESIS AND METASTATIC SPREAD OF OVARIAN CANCER A. Teterin Tutor: A. Major GENEVA 2000 Page 2 Definition and mechanism of angiogenesis u Angiogenesis is the process of new capillaries developing from preexisting vessels. u The mechanism of angiogenesis involves proliferation of capillary endothelial cells. Page 3 Regulation of angiogenesis u It is a complex issue in which a delicate balance between promotors and inhibitors is maintained. u Disturbance of this balance may result in a disrupted physiologic state or various pathologic conditions. Source: Abulafia O,Sherer DM. Angiogenesis in the ovary. Am J Obstet Gynecol 2000; Jan V 182 N 1, 1: 240-246. Page 4 Regulation factors Primary promotors of angiogenesis: ...

ovarian cancer Nutritional Supplementation and Fatigue in an Ovarian Cancer Patient Lisa Colodny, Pharm D., BCNSP Abstract Fatigue associated with chemotherapy can range from mild to severe depending on the regimen administered and the specific type of cancer . The etiology of fatigue is not well understood and many causes are proposed including a deficiency in the body to effectively utilize dietary nutrients. Therefore, the case of a 47 year old female recently diagnosed with Stage I ovarian carcinoma for which she received chemotherapy along with dietary supplementation was reviewed. Baseline fatigue levels were obtained prior to initiation of nutritional therapy and monitored for at least 3 months. During the treatment and supplement period, significant improvement in fatigue, nausea, vomiting, diarrhea, and over all general well being was reported. Additionally, hematological monitors and cancer ...

EPIDEMIOLOGY OF OVARIAN CANCER IN ILLINOIS by Holly L. Howe, Ph.D. Division of Epidemiologic Studies A Publication of the Illinois Department of Public Health Division of Epidemiologic Studies Springfield, IL 62761 February 1996 Page 2 Suggested Citation Howe HL. Epidemiology of ovarian cancer in Illinois. Epidemiologic Report Series 96:2 Springfield, IL: Illinois Department of Public Health, February 1996. Copyright Information All material in this report is in the public domain and may be reproduced or copied without permission; citation as to source, however, is appreciated. Page 3 1 EPIDEMIOLOGY OF OVARIAN CANCER IN ILLINOIS INTRODUCTION Advocacy groups clamor for more effective early detection of ovarian cancer in the hope that it will reduce the ...

ovarian cancer Ovarian Cancer : The Facts What is it? Ovarian Cancer originates in the inner tissue or outer lining of the ovaries. The ovaries are part of the female reproductive system. They are solid and almond shaped and located in the lower abdomen/pelvic area. Females naturally have two ovaries, one on each side of the uterus, with each connected to a fallopian tube leading to the uterus. The ovaries produce female hormones, especially estrogen and progesterone, which are responsible for the development of breasts and body shape and produce egg cells. Every 28-30 days in the menstrual cycle, one ovary releases a mature egg cell. Throughout the lifetime of a woman, and especially at different points in her menstrual cycle, the ovaries routinely change shape, position, and cell makeup. After menopause around age 45-50, ...

ovarian cancer Ovarian Cancer : Treatment Options How is it treated? There are different types of treatments for Ovarian Cancer , each with the goal of removing, destroying, or controlling the disease. When deciding on a treatment method, doctors consider the patient?s stage of life, general health, and the size and location of any tumors. In most cases of Ovarian Cancer , a combination of surgery and either chemotherapy or radiation is used. Surgery for Ovarian Cancer Surgery is the most common treatment used for Ovarian Cancer . The goal of the surgery is to remove as much of the visible cancer as possible. Surgery for Ovarian Cancer is usually followed by chemotherapy (or another non-surgical treatment) to try and kill any cancer cells that could not be removed or were undetected at ...

The Community Outreach Education Program of the Molecular Toxicology Center Presents: Breast and Ovarian Cancer : Genetic and Environmental Factors Special Guests: • Dr. Barbara Davis , Acting Chief, Laboratory of Women’s Health, National Institute of Environmental Health Sciences • Dr. Claire Bradley, Suffolk County Commissioner of Health • Lorraine Pace, Breast cancer educator and activist For More Information Contact: 631-444-2167 Come hear about the latest cutting edge research on the prevention and diagnosis of Breast & Ovarian Cancer ! Community Collaborators: • Suffolk County Department of Health • The Cancer Center of Stony Brook • The South Fork Breast Health Coalition • Cancer Survivors Center ...

ovarian cancer Debulking in Ovarian Cancer Ashraf Fawzy Nabhan Assistant Prof. of Obstetrics & Gynecology Ain Shams University, Cairo, Egypt Introduction Surgery is an essential in treating ovarian cancer . Diagnosis, staging, and therapy are performed at the time of laparotomy Debulking (cytoreduction) is the surgical approach for ovarian carcinoma Patterns of spread Direct extension Exfoliation of clonogenic cells Lymphatic spread Rationale of debulking Cell kinetics Log Cell-kill hypothesis Gompertizian Growth hypothesis Cell mutations Goldie-Coldman hypothesis Surgical staging Vertical incision Peritoneal washings TAH plus BSO Pelvic & abdominal biopsies Pelvic and paraaortic lymphadenectomy appendectomy ...

National Overview Ovarian Cancer Services Clinical Standards Board for Scotland www.clinicalstandards.org Page 2 © CSBS 2002 ISBN 1-903766-95-8 First published March 2002 Further details on the process by which the Board is achieving its objectives can be found in the comprehensive Clinical Standards Board for Scotland (CSBS) Quality Assurance & Accreditation Manual (August 2000). Copies of the Clinical Standards for Gynaecological ( Ovarian ) Cancer are also available from CSBS. The CSBS consents to the photocopying, electronic reproduction by ‘uploading’ or ‘downloading’ from the website, retransmission, or other copying of the findings of this report for the purpose of implementation in NHSScotland. Clinical Standards Board for Scotland Elliott House 8-10 Hillside Crescent Edinburgh EH7 5EA Copies of ...

OVACOME FACTSHEET 25 An Overview of Ovarian Cancer This factsheet sets out the different types of ovarian cancer , their characteristics and treatment differences where they exist. It is meant as a resource for readers who remain confused about this complicated issue. Ovarian cancer is classified into different types on the basis of its histological appearance – that is, how it looks to the pathologist down the microscope. The majority of ovarian cancers fall within the category of epithelial ovarian cancer . The remaining 10% consist of rare types. Epithelial Ovarian Cancer The greatest clinical challenge of the gynaecological cancers. Approximately 6800 new cases are diagnosed annually and this figure is rising. In the UK the overall five-year survival is around 28%. Optimists like me hope this figure is also ...

1 ALLIANCE ACTION Volume 5 , Number 3 Summer 2002 Ovarian Cancer National Alliance Ovar’coming Together Our Mission: To conquer ovarian cancer by uniting organizations and individuals in a national movement 910 17th Street, NW, Suite 413 Washington, DC 20006 Telephone: 202-331-1332 Email: ocna@ovariancancer.org Web site: www.ovariancancer.org IN THIS ISSUE: Conference 1 Fifth Anniversary 1 View from the Hill 2 Destination Health 3 Research News 4 Alliance Interns 4 Women Like You 5 Public Education 6 September Events 7 OC Symposium 8 T hese are just a few of the ovarian cancer ...

AYRSHIRE AND ARRAN HEALTH BOARD Strategy for Ovarian Cancer “Working with people to improve health” March 2001 Page 2 2 CONTENTS PAGE FOREWORD.4 INTRODUCTION..5 RECOMMENDATIONS 6 PROJECT BOARD MEMBERSHIP.7 BACKGROUND..8 U.K. I NCIDENCE .8 S URVIVAL .8 B ORDERLINE T UMOURS .8 I NTERNATIONAL C OMPARISONS OF I NCIDENCE R ATES 9 I NCIDENCE OF O VARIAN C ANCER IN A YRSHIRE AND A RRAN ..9 E XTENT OF S URGERY 10 G ENETICS 11 S ...

July, 2002 Ovarian Cancer in Ohio, 1999 This Report Contains: • Ovarian Cancer Incidence by Race, Age and Stage at Diagnosis. • Ovarian Cancer Survival by Stage. • Ovarian Cancer Risk and Protective Factors. The Ohio Cancer Incidence Surveillance System Cancer of the ovary made up 3.5 percent of the incident (newly diagnosed) cancers among females reported to the Ohio Cancer Incidence Surveillance System (OCISS) in 1999 (Table 1). For this period, the age-adjusted ovarian cancer incidence rate was 15.3 cases per 100,000 female Ohio residents, which is 10% lower than the 1999 U.S. rate (from the Surveillance, Epidemiology and End Results Program) of 17.0 per 100,000. In 1999, the age-adjusted mortality rate was 8.6 deaths ...

ovarian cancer What Is the Role of Laparascopic Surgery in Ovarian Cancer ? N. Abu-Rustum Memorial Sloan-Kettering Cancer Center, New York, U.S.A. The role of laparoscopy in ovarian cancer surgery may be divided into the following categories: 1- laparoscopic staging of a pparent early ovarian cancer 2- laparoscopic assessment of disease extent and potential for resectability 3- hand-assisted laparoscopy for resection of selected cases of advanced ovarian cancer 4- laparoscopic reassessment, or second-look operation, or rul e out recurrence. Laparoscopic staging of apparent early ovarian cancer may be accomplished in patients where disease appears limited to the adnexa. For example a completely resected complex adnexal mass with intraoperative frozen-section revealing maligna ncy and no obvious limitation to complete laparoscopic staging. Laparoscopic staging may also ...

Fox Chase Cancer Center 2001 Scientific Report Drug Resistance in Model Systems. Hamilton, Ozols, Selvakumaran, Williams, Bao, Bingham, Schoenberger The aggressive therapy of ovarian cancer includes, as a cornerstone, cisplatin or one of its analogs. Thus, our investigations of the mechanisms of drug resistance in ovarian can- cer cells primarily involve the study of mecha- nisms of platinum resistance. One approach we have used to study this problem has been to produce cisplatin-resistant ovarian cancer cell lines by exposure of drug sensitive cell lines to increasing concentrations of cisplatin. The most resistant of these variants, C200, is nearly 500-fold resistant to cisplatin. These cell lines show a complex cross-resistance phenotype typical of clinical ovarian cancer ; they are cross-resistant to carboplatin, tetraplatin, mel- phalan, ...

Dear Friend: As public education director of the Ovarian Cancer National Alliance, I wanted to respond to you about the e-mail about “Carolyn’s Story” that has been circulating recently and draw on this opportunity to share important information about the CA-125 blood test. In case you are not familiar with the Alliance, we are a survivor-run organization with the goal of increasing public and professional understanding of ovarian cancer on the national level, advocating for more effective diagnostics, treatments and a cure. One of our major activities is a public education initiative – taking as it’s philosophy and mission: “ Ovarian Cancer : Until There’s a Test, AWARENESS is Best” – which, we hope, will raise awareness among women and physicians around the country and familiarize them with the most accurate and up to date information on ovarian cancer . Unfortunately, Carolyn’s ...

Evidence based management of breast/ ovarian cancer risk in BRCA1/2 carriers D Gareth R Evans Christie and St Mary’s Hospital Manchester UK UK Forum for Genetics and Insurance October 2000 Page 2 Reproductive/hormonal factors in BRCA1/2 carriers Effect on age at diagnosis of breast cancer OCP use RR onset 95% CI p value Ever use from menarche No 1.000 Yes 3.55 1.42-8.86 0.0065 from dob No 1.000 Yes 3.46 1.38-8.68 0.008 Page 3 Effects of reproductive factors on breast cancer risk in BRCA1/2 carriers RESULTS * Questionnaires returned on 50/60 affected, 25/30 unaffected * Mean/Median/mode age at diagnosis breast cancer 41-44 years * Current age distribution 28-84; affected 50.6, unaffected 44.6 * Mean ...

OCNA Access to Specialty Care for Women with Ovarian Cancer : Why Gynecologic Oncologists Are Essential to the Survival of These Women This year, approximately 23,300 women will be diagnosed with ovarian cancer , and an estimated 14,000 women will die of the disease. Fifty percent of women diagnosed with ovarian cancer will die from the disease within five years, an unacceptably high mortality rate that can in part be mitigated by access to proper specialty care. Over the past two decades, research has shown that referral to a gynecologic oncologist is one of the top factors in increasing ovarian cancer survival rates, as well as decreasing rates of recurrence. What is a Gynecologic Oncologist? A gynecologic oncologist is an obstetrician/gynecologist who specializes in the diagnosis and treatment of women with cancer of the reproductive organs. After completing a four-year ...

Prudential Financial is a service mark of The Prudential Insurance Company of America, Newark, NJ and its affiliates The Prudential Insurance Company of America 751 Broad Street, Newark, NJ 07102-3777 RX53 DOC IFS-A013024, Ed. 03/02, Exp. 09/03 125 Ovarian Cancer Ovarian cancer accounts for 5% of all cancers in women and is most common in the 40-70 year age group. The incidence is increasing in highly industrialized countries and it is more common in women of higher socioeconomic status. The latter may be due to the smaller number of pregnancies in that group. Women who have not borne children are at an increased risk of ovarian cancer . Other risk factors include: early menopause, high fat diet, positive family history, and previous irradiation of the pelvic organs. Factors that suppress ovulation, such as pregnancy and the use of birth control pills, protect against this ...

What are the facts on Ovarian Cancer ? Garvan Institute of Medical Research What is ovarian cancer ? The ovaries are small almond-shaped organs located at both sides of the uterus. They are responsible for producing ova- the female reproductive cells, and the hormones oestrogen and progesterone. Ovarian cancer occurs when the normal division and growth of ovarian cells is disrupted, leading to an uncontrollable build up of cells. These abnormal build- ups are typically in the epithelial cells covering the ovary, but can also happen in the hormone producing tissues or in the ovum itself. Without appropriate treatment, the abnormal cancer cells may spread to nearby tissues or organs. How common is it? Ovarian cancer is the fourth leading cause of female cancers with 1 in 90 women estimated to develop the disease at ...

ovarian cancer Ovarian Cancer and High-Risk Women: Implications of Prevention, Screening and Early Detection Monday, May 6 & Tuesday, May 7, 2002 Pittsburgh, Pennsylvania Sponsored by University of Pittsburgh Graduate School of Public Health Magee-Womens Hospital of UPMC Health System University of Pittsburgh Cancer Institute University of Pittsburgh School of Medicine Center for Continuing Education in the Health Sciences Who Should Attend The purpose of this international symposium is to bring together experts in ovarian cancer research, clinicians, public health policy, and consumer advocates to discuss the scientific and health implications of prevention, screening, and early detection modalities in women at high risk for ovarian cancer . Participation by all individuals is encouraged. Advance notification of any special ...

Post Treatment Surveillance for Women with Epithelial Ovarian Cancer Goal: Surveillance is meant to identify recurrence. There are treatment options for recurrent disease though they are not curative. Early detection of recurrence does not change outcome. Therefore surveillance should be flexible. • These guidelines apply to women who have completed primary therapy (surgery with removal of both ovaries plus Platinum based chemotherapy) and are without evidence of disease. • Germ cell tumors and stromal tumors of the ovary are rare and have different treatment options as well as different serum markers. Those patients will require modification of the guideline. • Borderline tumors of the ovary have a better prognosis and are treated surgically both for primary and recurrent disease. Effective treatment for recurrence raises the value of surveillance for these patients. ...

VI-1 Section VI. O VARIAN C ANCER R ESEARCH P ROGRAM CONTENTS The Disease History of the OCRP Program Background Congressional Appropriation and Funding History FY99 Program FY00 Program Scientific Achievements Summary FY00 Integration Panel Members Page 2 VI-2 The Disease Ovarian cancer ranks first among gynecological cancers in the number of new deaths it causes in the United States each year. An estimated 23,100 women will be diagnosed with and 14,000 will die from ovarian cancer in 2000 in the United States. 1 Ovarian cancer is often without overt or specific symptoms until late in the disease process. The overall 5-year ...

VI-1 Section VI. O VARIAN C ANCER R ESEARCH P ROGRAM CONTENTS The Disease History of the OCRP Program Background Congressional Appropriation and Funding History FY00 Program FY01 Program Scientific Achievements Summary FY01 Integration Panel Members Page 2 VI-2 The Disease Ovarian cancer is projected to be the fifth most common cause of cancer death among women in the United States in 2001. This year an estimated 23,400 women will be diagnosed with and 13,900 will die from ovarian cancer in the United States. Among gynecological cancers in 2001, ovarian cancer ranks second in the number of new cases and first in the number of cancer deaths. ...

ovarian cancer Ovarian Cancer : Diagnosis and Screening in Primary Care Elise M. Hughes-Watkins, M.D. November 30, 2001 Ovarian Cancer : Burden of suffering 4th leading cause of cancer death in women in the U.S. (after lung, breast and colon) Overall 5-year survival rate is 35% The “silent killer”: asymptomatic in early stages 75% diagnosed with advanced stage disease; 5-year survival only 10-28% Woman’s lifetime risk of dying from ovarian cancer is 1.1% Cancer Incidence and Deaths in U.S.Women in 2000 Adapted from Paley,P, Screening for the major malignancies affecting women: Current guidelines. Am J Obstet Gynecol 2001;184: 4,600 12,800 Cervical 6,500 36,100 Endometrial 14,000 23,100 Ovarian ...